This retrospective study was conducted to determine whether the addition of a third injection of
biphasic insulin aspart 70/30 (
BIAsp 30) just before lunch in older patients with
type 2 diabetes who did not achieve goals with a twice-daily (BID) regimen would optimize
glycemic control in a clinical practice setting. A retrospective chart analysis was conducted. In 12 patients aged 52 to 80 y with
type 2 diabetes that had been diagnosed between 5 and 24 y earlier and who remained on oral antidiabetes agents, a third injection of
BIAsp 30 was added because optimal
glycemic control (
glycosylated hemoglobin [HbA1c]<7%) was not achieved on a BID regimen. Changes in HbA1c,
body weight, total
insulin dose, and frequency of
hypoglycemia were analyzed after 6 mo of three times daily (TID) treatment. Mean HbA1c decreased from 8.4% to 7.2%. An HbA1c goal of <7% was attained by 58% of patients. Although the total
insulin dose increased by 11% with the TID regimen, pre-breakfast and predinner doses decreased by 15%. No patient experienced major
hypoglycemia on BID or TID dosing. With the TID regimen, no minor
hypoglycemic events were reported by patients and mean
body weight decreased by 2.25 lb. The addition of a third injection of
BIAsp 30 substantially improved HbA1c and decreased
body weight and the incidence of
hypoglycemia in 12 patients with
type 2 diabetes who did not achieve optimal
glycemic control on a BID regimen.